These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2415808)

  • 61. Glucose metabolism in thyroid disease.
    Lamberg BA
    Acta Med Scand; 1965 Sep; 178(3):351-62. PubMed ID: 5829109
    [No Abstract]   [Full Text] [Related]  

  • 62. Drug interactions with cimetidine: an update.
    Gerber MC; Tejwani GA; Gerber N; Bianchine JR
    Pharmacol Ther; 1985; 27(3):353-70. PubMed ID: 2864708
    [No Abstract]   [Full Text] [Related]  

  • 63. Drug interactions with anticoagulants.
    Sigell LT; Flessa HC
    JAMA; 1970 Dec; 214(11):2035-8. PubMed ID: 5536475
    [No Abstract]   [Full Text] [Related]  

  • 64. Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism.
    Lumholtz B; Siersbaek-Nielsen K; Skovsted L; Kampmann J; Hansen JM
    Clin Pharmacol Ther; 1975 Jun; 17(6):731-4. PubMed ID: 1139863
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A route dependent bioavailability in active metabolite suggested in riboflavin-5'-phosphate pharmacokinetics.
    Morita K; Hanano M; Sugiyama Y; Awazu S
    Chem Pharm Bull (Tokyo); 1977 Oct; 25(10):2675-68. PubMed ID: 589711
    [No Abstract]   [Full Text] [Related]  

  • 66. Pulmonary disease and drug kinetics.
    du Souich P; McLean AJ; Lalka D; Erill S; Gibaldi M
    Clin Pharmacokinet; 1978; 3(4):257-66. PubMed ID: 354634
    [No Abstract]   [Full Text] [Related]  

  • 67. Urine data analysis for pharmacokinetics of aminopyrine and its metabolites in man.
    Koizumi T; Ueda M; Takada S
    Chem Pharm Bull (Tokyo); 1974 Apr; 22(4):894-906. PubMed ID: 4419027
    [No Abstract]   [Full Text] [Related]  

  • 68. Effect of beta-blockers on thyroid hormone.
    Bax ND; Lennard MS; Tucker GT
    Br Med J; 1980 Nov; 281(6250):1283. PubMed ID: 6107168
    [No Abstract]   [Full Text] [Related]  

  • 69. [Biopharmaceutical examination of various anticoagulants from the indandione-1,3 group].
    Brandys J
    Acta Pol Pharm; 1977; 34(5):545-6. PubMed ID: 602800
    [No Abstract]   [Full Text] [Related]  

  • 70. Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man.
    Teunissen MW; van der Veen EA; Doodeman PJ; Breimer DD
    Eur J Clin Pharmacol; 1984; 27(1):99-103. PubMed ID: 6489432
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Influence of thyroid status on plasma half-life of antipyrine in man.
    Eichelbaum M; Bodem G; Gugler R; Schneider-Deters D; Dengler HJ
    N Engl J Med; 1974 May; 290(19):1040-2. PubMed ID: 4821905
    [No Abstract]   [Full Text] [Related]  

  • 72. Drug pharmacokinetics in thyroid dysfunction.
    Rodighiero V
    Minerva Endocrinol; 1985; 10(2):97-113. PubMed ID: 2415808
    [No Abstract]   [Full Text] [Related]  

  • 73. Drug metabolism in thyroid disease.
    Eichelbaum M
    Clin Pharmacokinet; 1976; 1(5):339-50. PubMed ID: 797503
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Influence of thyroid dysfunction on drug pharmacokinetics.
    Shenfield GM
    Clin Pharmacokinet; 1981; 6(4):275-97. PubMed ID: 6166422
    [No Abstract]   [Full Text] [Related]  

  • 75. Unaltered metabolism of phenytoin in thyroid disorders.
    Mølholm Hansen J; Skovsted L; Kampmann JP; Lumholtz BI; Siersbaek-Nielsen K
    Acta Pharmacol Toxicol (Copenh); 1978 May; 42(5):343-6. PubMed ID: 581029
    [TBL] [Abstract][Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.